

# Yuet Ming Rebecca Chin

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1905086/yuet-ming-rebecca-chin-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22  
papers

1,539  
citations

16  
h-index

22  
g-index

22  
ext. papers

1,723  
ext. citations

12.6  
avg, IF

4.53  
L-index

#	Paper	IF	Citations
22	PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex. <i>Cancer Discovery</i> , <b>2015</b> , 5, 1194-2004	24.4	220
21	mTOR drives its own activation via SCF( $\beta$ TrCP)-dependent degradation of the mTOR inhibitor DEPTOR. <i>Molecular Cell</i> , <b>2011</b> , 44, 290-303	17.6	191
20	Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. <i>Cellular Signalling</i> , <b>2009</b> , 21, 470-6	4.9	188
19	Acetylation-dependent regulation of Skp2 function. <i>Cell</i> , <b>2012</b> , 150, 179-93	56.2	153
18	The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. <i>Molecular Cell</i> , <b>2010</b> , 38, 333-44	17.6	137
17	Targeting Akt3 signaling in triple-negative breast cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 964-73	10.1	109
16	3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. <i>Cancer Research</i> , <b>2009</b> , 69, 6299-306	10.1	106
15	NFAT promotes carcinoma invasive migration through glypican-6. <i>Biochemical Journal</i> , <b>2011</b> , 440, 157-66	3.8	70
14	Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt. <i>Molecular Cell</i> , <b>2016</b> , 62, 929-942	17.6	66
13	PTEN-deficient tumors depend on AKT2 for maintenance and survival. <i>Cancer Discovery</i> , <b>2014</b> , 4, 942-55	24.4	62
12	Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor. <i>Molecular Cancer Research</i> , <b>2009</b> , 7, 425-32	6.6	58
11	Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1964-74	6.1	35
10	RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. <i>Cancer Research</i> , <b>2013</b> , 73, 50-61	10.1	32
9	Akt2 regulates expression of the actin-bundling protein palladin. <i>FEBS Letters</i> , <b>2010</b> , 584, 4769-74	3.8	27
8	Mechanism for removal of tumor necrosis factor receptor 1 from the cell surface by the adenovirus RIDalpha/beta complex. <i>Journal of Virology</i> , <b>2005</b> , 79, 13606-17	6.6	25
7	Inhibition of tumor necrosis factor (TNF) signal transduction by the adenovirus group C RID complex involves downregulation of surface levels of TNF receptor 1. <i>Journal of Virology</i> , <b>2004</b> , 78, 13113-21	6.6	20
6	Akt-ing up on SRPK1: oncogene or tumor suppressor?. <i>Molecular Cell</i> , <b>2014</b> , 54, 329-30	17.6	14

5	Adenovirus RID complex enhances degradation of internalized tumour necrosis factor receptor 1 without affecting its rate of endocytosis. <i>Journal of General Virology</i> , <b>2006</b> , 87, 3161-3167	4.9	9
4	Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling. <i>Nature Communications</i> , <b>2021</b> , 12, 2242	17.4	9
3	ANLN Enhances Triple-Negative Breast Cancer Stemness Through TWIST1 and BMP2 and Promotes its Spheroid Growth. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 700973	5.6	6
2	Cancer stem cells: advances in biology and clinical translation-a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , <b>2021</b> ,	6.5	1
1	TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis. <i>British Journal of Cancer</i> , <b>2021</b> ,	8.7	1